We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -1.61% | 3.05 | 3.00 | 3.10 | 3.15 | 3.05 | 3.10 | 1,785,708 | 13:41:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.16 | 2.75M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/11/2021 14:42 | Physiomics PYC in July talking about the FDA's 'Project Optimus' a major FDA project focused on Precision Dosing. Physiomics have said previously they are getting exposure to Regulators via some of their client engagements What would happen to PYC valuation if they announced a tie-up with the FDA ?! PYC Mkt Cap of 7m is ridiculous given a client list including likes of Merck, Astellas, Bicycle Therapeutics, Numab, CellCentric etc either Big Pharma or leading edge First-in-Class or Best-in-Class emerging biotechs | the stigologist | |
13/11/2021 01:38 | Didums stuck in a pile of poo called pyc So has to ramp it on sar and Val both of which have gone up fivefold I'm laughing my head off lolHahahahaha Sorry for your losses Stig | nico115 | |
12/11/2021 22:57 | I must admit it's a very disappointing deal given the sort of deals other similar stage small bio Companies have been able to extract Fail on at least 3 fronts 1. Size of upfront - very poor (I expected $5-10m upfront) 2. Timing (the revenues are back end loaded even the supposed 'upfront' is a 2023 event) 3. Quality of partner (never heard of them, not a Big name Pharma or even Best/First in Class Bio) The whole point of licensing tech out is so a bigger (balance sheet, human resources) more experienced, more specialist player can VALIDATE your IP, and leverage it into commerciality quicker by using their resources to overcome regulatory and commercial barriers. Signing a deal with a no name company with no balance sheet is a bad deal no matter how people spin it Snake nick slater will start dumping soon so watch your backs | the stigologist | |
12/11/2021 21:49 | Im not convinced that comment is that great - you let a lot of of people down. | ragnarr | |
12/11/2021 20:14 | I’m not convinced the deal is that great. Suzy let a lot of people down | francoismyname | |
12/11/2021 14:37 | PYC Physiomics RNS today confirming they are presenting alongside BCYC Bicycle on Bicycle's BT7480 PYC Mkt Cap : £6m BCYC Mkt Cap : $1600m Physiomics helped them with the Modelling and Simulation of BT7480 This presentation at a major Global Cancer Conference is going to be great marketing for PYC who just recently took on ,for the first time, a dedicated Business Development Director from FAB Fusion Antibodies This isn't even the real transformational part of the business which is going to be when they use their expertise in Modelling and Simulation gained thru consulting work for leading edge bios and Pharmas and put together dosing apps which can be used in NHS/US clinical use and where they then have potential for software IP licensing type deals Chart looks ready to break out from a long and large pennant formation. Just popping its head above 200 day Moving Average as well today. Bicycle regard themselves as 'well positioned to be the next generation of targeted oncology therapeutics' which places them in multi-billion blockbuster drug territory of antibodies and antibody-drug-conjug Given their IP is based on Nobel prize winning science and they have partners like Roche Genentech and AstraZeneca its a great Company for PYC Physiomics to ride the coat-tails of | the stigologist | |
12/11/2021 11:31 | Volume pretty much dried up . Let's hope it settles around this level to set a strong base for the next stage up | 1savvyinvestor | |
11/11/2021 18:21 | GENinCode (GENI), 38p, market cap. £36.41M. 22/07/2021 06:00 UK Regulatory (RNS & others) GENinCode PLC Admission to trading on AIM & First Day of Dealing LSE:GENI Genincode Plc " ... The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in certain European countries and is also targeting the UK and US. ..." €50 million equates to about £43M. at the current exchange rate. Compared to GENI's current market cap. at 38p of £36.4M. With GENI cash reserves post admission at 31 July 2021 of £16.7M. Moreover, the sums invested have resulted in great products that are now being commercialised, so should actually be worth more. diversification 6 Nov '21 - 17:39 - 20 of 24 0 2 0 "News must now be imminent as the November window closes and we should see both a winter rally in the broader markets and a deluge of news from Genincode. Time to be excited." GENinCode (GENI): | hedgehog 100 | |
11/11/2021 08:52 | two up coming presentations and q and a sessions must be positive for the share price | goldie40 | |
10/11/2021 20:29 | I have a transcript of the recent Midweek Roast interview, if any one is interested I can post it. | ragnarr | |
10/11/2021 15:55 | Feels like the ship has steadied and some good chunky individual buys yesterday and today so hopefully could be turning the corner. | wulber | |
10/11/2021 14:53 | Nice straight 105k buy | reidy66 | |
10/11/2021 12:38 | Stig PYC look a decent company doing good things. The problem, however is they are a support business and have not found any way of monetising their work. VAL is the closest they have come and you trash Val all the time!! Until PYC get more royalty deals on drugs they support then they will never make any money on their business model. They are low risk/low reward - well losses so there is no high risk/high reward dynamic to play with PYC | dope007 | |
10/11/2021 12:13 | HUGE Validation for Physiomics PYC Presenting alongside their client BCYC Bicycle Therapeutics at a major Cancer Conference Bicycle Therapeutics set up by Nobel prize winning scientists pioneering a whole new modality of treatments which look to be showing evidence of being better that ADCs (Antibody Drug Conjugates) Physiomics has provided data modelling for ALL Bicycle's oncology pipeline clinical assets PYC Mkt Cap £6m BCYC Mkt Cap $1600m UK market missing what NASDAQ listed but UK company BCYC Bicycle is achieving (including a $1bn+ headline deal with Roche Genentech) | the stigologist | |
10/11/2021 09:58 | Usually when they get above a certain weighting in the portfolio arab | volsung | |
10/11/2021 09:47 | Well done Volsung, When do you sell any of the shares you buy cheap ? | arab3 | |
10/11/2021 09:41 | Those shares I bought at 31p lookin’ darn purty | volsung | |
10/11/2021 09:37 | Another p n d | jaforsadi | |
10/11/2021 09:16 | I think people simply waking up to the fact that the legacy cancer lP and how advanced it is, is massively undervalued and worthy of a company with a mkt cap of between £50 and £75 mn pre-deal and probably in the same league as its peers post-deal. | wulber | |
10/11/2021 09:02 | 36p what is happening here?? | cparry1989 | |
10/11/2021 08:54 | I was not expecting the share price to see 35p today hope this keeps going | cparry1989 | |
09/11/2021 15:25 | I meant buy! | sean cadman | |
09/11/2021 15:24 | Nice 280,000 but! | sean cadman | |
09/11/2021 12:35 | Suzy and co, look after Suzy and co . The Rampers have had there way within this so called biotech , Sold down the river and more exorbitant salaries etc . 0n and on , Jam tomorrow , Free beer always on the morrow. Or was that borrow . Beg borrow steal Ltd well known firm of sharks. Deal of a lifetime , No chance there never was. | gpferg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions